Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Annexon (Nasdaq: ANNX) announced inducement equity awards to two new non-executive employees under its 2022 Employment Inducement Award Plan, approved on January 9, 2026 in accordance with Nasdaq Listing Rule 5635(c)(4). In aggregate the hires received options to purchase 155,000 shares of common stock. The options have a 10-year term, an exercise price of $6.16 per share (the closing price on January 15, 2026, the grant date), and vest over 4 years with 25% vesting at the first anniversary and the remainder vesting monthly thereafter, subject to continued service.

News Market Reaction

+1.48%

1 alert

+1.48% News Effect

On the day this news was published, ANNX gained 1.48%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Target population: nearly 10 million people New employees: 2 non-executive employees Option shares granted: 155,000 shares +5 more

8 metrics

Target population nearly 10 million people Neuroinflammatory diseases addressed by Annexon platform

New employees 2 non-executive employees Recipients of inducement equity awards

Option shares granted 155,000 shares Aggregate options to purchase Annexon common stock

Exercise price $6.16 per share Closing price on January 15, 2026, used as grant exercise price

Option term 10 years Duration of inducement stock options

Vesting period 4 years Total vesting duration for options

Initial vesting cliff 25% Portion vesting on first anniversary of grant date

Ongoing vesting rate 1/48th monthly Monthly vesting of remaining option shares after year one

Market Reality Check

Price: $5.04 Vol: Volume 1,475,871 is 0.51x...

low vol

$5.04 Last Close

Volume Volume 1,475,871 is 0.51x the 20-day average of 2,896,350, indicating lighter-than-usual trading. low

Technical Shares around $6.07 were trading above the 200-day moving average at $2.92 before this announcement.

Peers on Argus

ANNX fell 7.78% while peers were mixed: NMRA down 7.76%, OMER down 1.4%, but ALE...

ANNX fell 7.78% while peers were mixed: NMRA down 7.76%, OMER down 1.4%, but ALEC, LCTX and MNPR up between 1.73% and 2.41%, pointing to stock‑specific pressure rather than a broad sector move.

Historical Context

5 past events · Latest: Jan 12 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 12	Platform milestones	Positive	+5.9%	Outlined 2026 priorities and multiple registrational milestones with cash runway guidance.
Jan 08	Regulatory submission	Positive	-4.3%	Filed MAA with EMA for tanruprubart in GBS with supporting Phase 3 data.
Jan 07	Conference presentation	Neutral	+8.4%	Announced presentation slot at J.P. Morgan Healthcare Conference with webcast access.
Dec 16	Inducement grant	Neutral	+2.1%	Granted a 19,000‑share stock option inducement with standard four‑year vesting.
Nov 14	Equity offering	Negative	+11.4%	Closed underwritten public offering of shares and pre‑funded warrants for $86.25M.

Pattern Detected

Recent news has produced mixed alignment, with both positive and dilutive events sometimes moving shares contrary to their apparent tone.

Recent Company History

Over recent months, Annexon has reported several material milestones. On Nov 14, 2025, it closed a public offering with gross proceeds of $86.25M. A prior 424B5 detailed a primary offering of 25,096,153 shares plus 3,750,000 pre‑funded warrants at $2.60 per share. In December 2025, it granted a 19,000‑share inducement option. Early January 2026 brought an MAA submission for tanruprubart in GBS and a broader 2026 strategy update with multiple registrational milestones. Today’s additional inducement grants fit within this ongoing capital formation and hiring cadence.

Market Pulse Summary

This announcement details inducement option grants for 155,000 shares to two new non‑executive emplo...

Analysis

This announcement details inducement option grants for 155,000 shares to two new non‑executive employees under Nasdaq Listing Rule 5635(c)(4), with a $6.16 exercise price and standard four‑year vesting. It continues a pattern of using targeted equity awards alongside larger capital‑raising steps and advancing regulatory milestones. Investors may watch how cumulative equity issuance, upcoming registrational events, and future hiring updates interact with Annexon’s existing $918,184,215 market valuation and trading trends.

Key Terms

nasdaq listing rule 5635(c)(4)

1 terms

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. Not financial advice.

BRISBANE, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on January 9, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).

In the aggregate, the new non-executive employees received options to purchase 155,000 shares of Annexon common stock. The options carry a ten-year term and an exercise price per share equal to $6.16, which was the closing price of Annexon’s common stock on January 15, 2026, the date of grant, and vest over 4 years, with 25% of the shares underlying the options vesting on the first anniversary of the grant date and an additional 1/48th of the shares vesting monthly thereafter, subject to continued service through the applicable vesting dates.

About Annexon

Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. Our founding scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss of function in a host of diseases. Our targeted therapies are designed to stop classical complement-driven neuroinflammation at its source to provide meaningful functional benefit and alter the course of disease. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.

Investor Contact:

Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com

FAQ

How many shares did Annexon grant in inducement awards on January 9, 2026 (ANNX)?

Annexon granted options to purchase 155,000 shares in aggregate to two new non-executive employees.

What is the exercise price and term for the Annexon (ANNX) inducement options granted in January 2026?

The options carry a 10-year term with an exercise price of $6.16 per share, equal to the closing price on January 15, 2026.

When do the Annexon (ANNX) inducement options vest?

They vest over 4 years: 25% on the first anniversary of the grant and the remainder monthly (1/48th) thereafter, subject to continued service.

Under what Nasdaq rule were Annexon's January 2026 inducement awards approved?

The awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Who received the Annexon (ANNX) inducement grants announced January 16, 2026?

The grants were made to two new non-executive employees under the company's 2022 Employment Inducement Award Plan.